[Relation of ME491/CD63 gene and integrin alpha5 in the invasion and metastases of ovarian cancer].
OBJECTIVE
To explore the expression and significance of ME491/CD(63) and integrin alpha5 protein and mRNA in ovarian cancer.


METHODS
The expression levels of ME491/CD(63) and integrin alpha5 proteins and mRNA were evaluated by using RT-PCR and hybridization in situ (HIS) in normal ovarian tissues (G(1)), ovarian benign tumor tissues (G(2)), ovarian borderline tumor tissues (G(3)) and ovarian cancer tissues (G(4)). The expression levels of ME491/CD(63) genes and proteins were analyzed by multivariant analysis and their effects on the invasion and metastases of ovarian cancer were explored and their correlation with age at surgery, metastatic sites, operation fashions, lymph status, operation pathological staging and pathological typing was studied.


RESULTS
The results showed the exact biological effects of ME491/CD(63) and integrin alpha5 in ovarian cancer tissues. The tendency of two methods is coincidence on the whole. There was positive expression of ME491/CD(63) and integrin alpha5, and ME491/CD(63) mRNA expression levels were 1.7 +/- 0.3 and 1.5 +/- 0.3, and integrin alpha5 mRNA expression levels were 1.7 +/- 0.3 and 1.5 +/- 0.3 in G(1) and G(2); ME491/CD(63) is 1.1 +/- 0.5, and integrin alpha5 is 1.1 +/- 0.5 in G(3); ME491/CD(63) is 0.6 +/- 0.4, integrin alpha5 is 0.6 +/- 0.4 in G(4); There was no significant relationship between gene expression and age at surgery or clinical-pathological staging (P > 0.05). There was significant difference between G(1), G(2) and G(3) (P < 0.01), while no difference between G(1) and G(2) (P > 0.05). Low expression levels in G(4) (III, IV) were observed. Significant differences were noted between expression levels in G(4) (III, IV) and in G(2), G(3) or G(4) (I, II; P < 0.01). There was significant difference between expression levels in tissues with lymph metastases and tissues without lymph metastases (P < 0.01).


CONCLUSIONS
ME491/CD(63) and integrin alpha5 are lowly expressed and negatively correlated with ovarian cancer. Different expression levels exist in tissues of late ovarian cancer, earlier ovarian cancer, benign ovarian tumor and borderline tumor. The changes of two genes are correlated with tumor differentiation degree, but not pathologic typing.
Xia
Zhi-jun
ZJ
Department of Obstetrics and Gynecology, Second Clinical College, China Medical University, Shenyang 110003, China.
Zhang
Shu-lan
SL
Zhou
Zhuo
Z
D000293:Adolescent; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000096:biosynthesis* / Q000235:genetics; D005260:Female; D006801:Humans; D039482:Integrin alpha5 / Q000096:biosynthesis* / Q000235:genetics; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology*; D010980:Platelet Membrane Glycoproteins / Q000096:biosynthesis* / Q000235:genetics; D012333:RNA, Messenger / Q000096:biosynthesis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D060149:Tetraspanin 30
D015703:Antigens, CD; C554586:CD63 protein, human; D039482:Integrin alpha5; D010980:Platelet Membrane Glycoproteins; D012333:RNA, Messenger; D060149:Tetraspanin 30